Literature DB >> 27246291

Symptomatic hypophosphataemic osteomalacia secondary to the treatment with iron carboxymaltose detected in bone scintigraphy.

M J Sangrós Sahún1, E Goñi Gironés2, A Camarero Salazar3, C Estébanez Estébanez4, M E Lozano Martínez5.   

Abstract

The development of hypophosphataemic osteomalacia has been linked with several treatments, mainly antiretroviral and intravenous iron administration. The frequency of the hypophosphataemia requires monitoring the phosphate after the administration of iron carboxymaltose. We describe a case of a woman with no calcium-phosphorous metabolism disorder, to whom this treatment was prescribed for anaemia due to menorrhagia and intolerance to oral iron. She started with oligoarticular pain, which was spreading with a significant functional loss. The relationship with the administration of intravenous iron was discovered when scintigraphic findings together with laboratory results led to a diagnosis of hypophosphataemic osteomalacia. The patient responded satisfactorily to treatment with phosphate both clinically and in the follow-up bone scintigraphy.
Copyright © 2016 Elsevier España, S.L.U. y SEMNIM. All rights reserved.

Entities:  

Keywords:  Bone scintigraphy; Ferric carboxymaltose; Gammagrafía ósea; Hierro carboximaltosa; Hipofosfatemia; Hypophosphataemia; Osteomalacia

Mesh:

Substances:

Year:  2016        PMID: 27246291     DOI: 10.1016/j.remn.2016.04.006

Source DB:  PubMed          Journal:  Rev Esp Med Nucl Imagen Mol        ISSN: 2253-654X            Impact factor:   1.359


  5 in total

1.  High-dose intravenously administered iron versus orally administered iron in blood donors with iron deficiency: study protocol for a randomised, controlled trial.

Authors:  Susanne Macher; Camilla Drexler; Ines Lindenau; Nazanin Sareban; Peter Schlenke; Karin Amrein
Journal:  Trials       Date:  2016-10-28       Impact factor: 2.279

2.  Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk.

Authors:  Benedikt Schaefer; Philipp Würtinger; Armin Finkenstedt; Vickie Braithwaite; André Viveiros; Maria Effenberger; Irene Sulzbacher; Alexander Moschen; Andrea Griesmacher; Herbert Tilg; Wolfgang Vogel; Heinz Zoller
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

3.  Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose.

Authors:  Benedikt Schaefer; Heinz Zoller; Myles Wolf
Journal:  J Clin Endocrinol Metab       Date:  2022-03-24       Impact factor: 5.958

4.  Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports.

Authors:  Tatiane Vilaca; Nalini Velmurugan; Christopher Smith; Bo Abrahamsen; Richard Eastell
Journal:  J Bone Miner Res       Date:  2022-05-07       Impact factor: 6.390

5.  High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment.

Authors:  Johannes M M Boots; Rogier A M Quax
Journal:  Drug Saf       Date:  2022-09-06       Impact factor: 5.228

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.